Cytokinetics, Inc.  

(Public, NASDAQ:CYTK)   Watch this stock  
Find more results for CYTK
-0.36 (-4.83%)
Jan 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.00 - 7.44
52 week 3.05 - 13.26
Open 7.38
Vol / Avg. 267,371.00/707,157.00
Mkt cap 259.56M
P/E     -
Div/yield     -
EPS -0.44
Shares 36.61M
Beta 1.15
Inst. own 61%
Feb 12, 2015
Q4 2014 Cytokinetics Inc Earnings Call - 4:30PM EST - Add to calendar
Feb 12, 2015
Q4 2014 Cytokinetics Inc Earnings Release - 4:00PM EST - Add to calendar
Feb 9, 2015
Cytokinetics Inc at Biotechnology Industry Organization CEO & Investor Conference - 11:30AM EST - Add to calendar
Jan 5, 2015
Cytokinetics Inc and Astellas Announce Expansion of Collaboration for Development of CK-2127107 in Spinal Muscular Atrophy Conference Call - Webcast
Dec 3, 2014
Cytokinetics Inc at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -63.42% -110.01%
Operating margin -63.71% -110.59%
EBITD margin - -109.18%
Return on average assets -26.13% -41.95%
Return on average equity -31.45% -54.15%
Employees 85 -
CDP Score - -


280 E Grand Ave
United States - Map
+1-650-6243000 (Phone)
+1-650-6243010 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cytokinetics, Incorporated (Cytokinetics) is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. The Company�s research and development programs relating to the biology of muscle function are directed to small molecule modulators of the contractility of cardiac, skeletal and smooth muscle. The cardiac muscle contractility program is focused on cardiac sarcomere, the basic unit of muscle contraction in the heart. Its lead drug candidate CK-2017357 is subject of a Phase IIa clinical trials program. CK-2017357 is useful in treating diseases or medical conditions associated with skeletal muscle weakness or wasting. In March 2010, CK-2017357 received an orphan drug designation from the FDA for the treatment of amyotrophic lateral sclerosis.

Officers and directors

L.Patrick Patrick Gage Ph.D. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Robert I. Blum President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Sharon A. Barbari Chief Financial Officer, Executive Vice President - Finance
Age: 60
Bio & Compensation  - Reuters
David W. Cragg Senior Vice President - Human Resources
Age: 58
Bio & Compensation  - Reuters
Bonnie A. Charpentier Ph.D. Senior Vice President - Regulatory Affairs and Compliance
Age: 60
Bio & Compensation  - Reuters
Fady I. Malik M.D., Ph.D. Senior Vice President - Research and Early Development
Age: 49
Bio & Compensation  - Reuters
Andrew A. Wolff M.D. Senior Vice President - Clinical Research and Development, Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Santo J. Costa Independent Director
Age: 68
Bio & Compensation  - Reuters
Denise M. Gilbert Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
John T. Henderson M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters